

Test Report

Ordered By

Name Name, MD, PhD.

Collection Date

00/00/0000

Specimen ID

000000

Patient Information

Name Name Name Date of Birth


Sex

M

Medical Record Number

00/00/0000 000000000

kidneyintelX.dkd LEVEL



In the clinical performance study*, approximately 17% (95% CI 12% to 22%) of patients with Moderate kidneyintelX.dkd Levels experienced progressive decline in kidney function decline within 5 years after their test result.

Signed

High

Name / Signature

Laboratory Director: Name Name

CLIA Number: 000000000

Renalytix, 101 6th Avenue, 3rd Floor, Room 324, New York, NY 10013

18.2% (9.1% - 30.9%)

Report Date

Time

00/00/0000 00:00 AM (UTC)

Percent of Patients Percent of Patients Experiencing Progressive Experiencing End kidneyintelX.dkd Decline in Kidney Stage Kidney Level Function (95% CI) Disease (95% CI) 4.6% (2.7% - 7.2%)0.0% Low Moderate 16.7% (12.1% - 22.2%)3.1% (1.2% - 6.2%)

*Based on clinical performance study results in the kidneyintelX.dkd Product Technical Sheet. The kidneyintelX.dkd Levels (Low, Moderate, and High) correlate with the probability of progressive decline in kidney function.

41.8% (28.7% - 55.9%)

To receive a kidneyintelX.dkd Product Technical Sheet, contact Client Services at (888) 203-2725 or at clientservices@renalytix.com.

kidneyintelX.com



renalytix™

kidneyintelX.dkd Product Technical Sheet (printed copy) is promptly provided at no cost upon request.